Contact us
Expertise in real world data
Why Oxon
Publications
OXON's record of being associated with top quality publications provides clients with the reassurance that they will receive scientific rigour in the design, analysis, interpretation of their studies as well as high quality reports and manuscripts:
· Abstracts

Pocock SJ, Brieger D, Gregson J, YanChen J, Cohen M, Goodman SG, et al. A
Novel Approach to Quantifying Risk of Major Cardiovascular Eventes in Patients 1-3 years Postmyocardial infarction: Insights from the Global Prospective TIGRIS Registry.
Journal of American College of Cardiology. 2019;73(9):83.


Laferriere C, Dion S, Major M, Nepal R, Vojicic J, Qizilbash N, et al. Decline in
Incidence of Hospitalization Due to Pneumococcal and All-Cause Pneumonia in Canadian Children, 2004 to 2015.
CIC2018.


Brieger D, Pocock SJ, Goodman SG, Westermann D, Blankenberg S, Nicolau JC, et al.
Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study.
European Heart Journal. 2018;39(suppl 1):1083.
Presented as an oral presentation at European Society of Cardiology in August 2018 by Prof David Brieger on behalf of the TIGRIS investigators
ASC2018.


Artime E, Vora P, Asiimwe A, Soriano-Gabarro M, Qizilbash N.
Quantitative Analysis of Survey Studies Assessing the Effectiveness of Risk Minimisation Measures: State of the Art.
ISPE2018.


Artime E, Shui I, Tcherny-Lessenot S, D’Arbigny P, Mendez I, Qizilbash N.
Pre/post survey to assess the effectiveness of updated Risk Minimisation Materials for an orphan disease: Wave 1 results.
DIA Europe2018.


Artime E, Kahlon R, Qizilbash N, MĂ©ndez I, Kou T.
Healthcare Professional Survey to Assess the Effectiveness of Abatacept (ORENCIA®) Patient Alert Cards.
ISPE2018.


Artime E, Kahlon R, Qizilbash N, MĂ©ndez I, Kou T.
Correlating soft and hard outcomes: Effectiveness of Abatacept (ORENCIA®) Patient Alert Cards in Rheumatoid Arthritis Patients.
ISPE2018.


Vora P, Artime E, Soriano-Gabarro M, Qizilbash N, Asiimwe A.
A Review of Cross-Sectional Survey Studies Evaluating Risk Minimisation Measures in European Union (EU) Using the EU Electronic Register of Post-Authorisation Studies
Pharmacoepidemiology and drug safety. 2017;26(Suppl 2):11.


Stack A, Blak B, Johnson M, Parsons V, Carpenter L, Maguire A, et al.
Association of incident gout with new-onset kidney failure in the UK health system.
Nephrology Dialysis Transplantation. 2017;32(S3):210-1.
EDTA2017


Qizilbash N, Gregson J, Johnson M, Pearce N, Douglas I, Wing K, et al.
Raised Blood Pressure as a Risk Factor For Vascular Dementia but Not Alzheimer’s Disease: A Cohort Of 2.6 Million People Over Two Decades.
Pharmacoepidemiology and drug safety. 2017;26(Suppl 2):456.
ISPE 2016


Qizilbash N.
Quantitative Review of Effectiveness of Risk Minimisation Measures in Surveys & Outcome Studies in Europe.
EMA Information Day2017.


Méndez I, Zagorska A, Artime E, Lefevre C, San José B, González García P, et al.
Characteristics And Treatment Patterns In Patients Treated For Relapsed Refractory Multiple Myeloma Over 3 Years: PREMIERE Study.
ISPOR2017.


Méndez I, Zagorska A, Artime E, Lefevre C, San José B, González García P, et al.
Treatment Strategies And Outcomes In Patients Treated For Relapsed Refractory Multiple Myeloma Over 3 Years: PREMIERE Study.
ISPOR2017.


Johnson M, Lefevre C, Evans D, Lacoin L, Ridha E, Maguire A, et al.
Which factors recorded during routine care predict treatment discontinuation of novel oral anticoagulants in European patients with non-valvular atrial fibrillation?
EP Eur Oxford University Press. 2017;19(suppl 3):iii151
ACC 2016


Fauchier L, Mouquet F, Duhot D, Stynes G, Vannier-Moreau V, Lefèvre C, et al.
Initiation of Oral Anticoagulant Therapy for Management of Non-Valvular Atrial Fibrillation: Patient Characteristics and Comparison of Persistence in France.
ACC2017.


Fauchier L, Mouquet F, Duhot D, Stynes G, Vannier-Moreau V, Lefevre C, et al.
Persistence after initiation of oral anticoagulant for atrial fibrillation in France.
EP Eur Oxford University Press. 2017;19(suppl 3):iii151
EHRA2017.


Fauchier L, Collings S, Johnson M, Stynes G, Evans D, Vannier-Moreau V, et al.
What are the differences in oral anticoagulant treatment persistence in non-valvular atrial fibrillation in Europe? Real-world studies in three European countries.
Journal of the American College of Cardiology. 2017;69(11):498


Artime E, Vora P, Asiimwe A, Soriano-Gabarro M, Qizilbash N.
Variability in Reporting Participation Data in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union.
Pharmacoepidemiology and drug safety. 2017;26(Suppl 2):425.
ICPE2017.


Artime E, Vora P, Asiimwe A, Soriano-Gabarro M, Qizilbash N.
Sampling Methods Used and Country Selection in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union.
Pharmacoepidemiology and drug safety. 2017;26(Suppl 2):425.
ICPE2017.


Artime E, Vora P, Alfaro-Oliver N, Asiimwe A, Soriano-Gabarro M, Qizilbash N.
Qualitative Approaches to Testing Data Collection Instruments in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union.
Pharmacoepidemiology and drug safety. 2017;26(Suppl 2):484.
ICPE2017.


Artime E, Kahlon R, Qizilbash N, Kou T.
Hybrid approach to the evaluation of the effectiveness of additional risk minimisation measures correlating process and outcome indicators at the individual-patient level.
MidISPE2017.


Ridha E, Johnson M, Lacoin L, Collings S, Parsons V, Kloss S, et al.
Differences in the characteristics of patients with non-valvular atrial fibrillation who are newly prescribed apixaban, rivaroxaban, dabigatran and VKA in general practice in the UK.
European Heart Journal. 2016;37(suppl 1):P52542
ESC; 2016.


Qizilbash N, Gregson J, Johnson M, Pearce N, Douglas I, Wing K, et al.
Blood pressure and risk of dementia in a cohort of 2.6 million people over two decades.
Pharmacoepidemiology and drug safety. 2016;25(Suppl 3):105.


Qizilbash N, Gregson J, Johnson M, Pearce N, Douglas I, Wing K, et al.
Body Mass Index and Risk of Parkinson’s Disease in a Cohort of Two Million People Over Two Decades.
Pharmacoepidemiology and drug safety. 2016;25(Suppl. 3):105


Qizilbash N.
Quantitative review of survey studies to assess the effectiveness of risk minimisation.
EMA information day2016.


Maguire A, Puelles J.
Identifying anti-TNF use for Crohn’s disease and ulcerative colitis in primary care.
Pharmacoepidemiology and drug safety. 2016;25(Suppl 1):518


Maguire A, Johnson M, Denning D, Ferreira G, Cassidy A.
Identification of rare diseases using electronic medical records - example of allergic bronchopulmonary aspergillosis in UK Primary Care Data.
Pharmacoepidemiology and drug safety. 2016;26(S2):S475


Lefevre C, Johnson M, Kloss S, Ridha E, Evans D, Maguire A, et al., editors.
What happens with oral anticoagulant treatment persistence during and after the initial 100 days of therapy? Findings from a real-world data study in Germany.
ESC; 2016.


Lefevre C, Johnson M, Collings S, Ridha E, Kloss S, Parsons V, et al., editors.
Does treatment persistence of oral anticoagulants change over time? Real-world evidence from a large cohort of atrial fibrillation patients treated with oral anticoagulants in the UK.
ESC; 2016.


Lefèvre C, Johnson M, Collings S, Evans D, Kloss S, Ridha E, et al.
Changes over time in treatment persistence of oral anticoagulants in patients with non-valvular atrial fibrillation.
Journal of American College of Cardiology. 2016;67(13):769


Lefèvre C, Johnson M, Collings S, Evans D, Kloss S, Ridha E, et al.
Comparison of treatment persistence in the real-world use of novel oral anticoagulants among patients with non-valvular atrial fibrillation.
American College of Cardiology. 2016;67(13):792


Lacoin L, Johnson M, Collings S, Lefevre C, Kloss S, Parsons V, et al.
Is there a difference in treatment persistence across oral anticoagulants? Results of a UK cohort study evaluating oral anticoagulation therapy in an atrial fibrillation population.
European Heart Journal. 2016;37(suppl 1):P2542
European Society of Cardiology ESC 2016.


Everage NJ, Maguire A, Mahadavan L, Wenten M.
Compliance with renal testing recommendations for fampiridine use in German population with multiple sclerosis.
Pharmacoepidemiology and drug safety. 2016;25(Suppl 3):311


Collings S, Johnson M, Kloss S, Evans D, Maguire A, Lefevre C.
Using Primary Care and Cardiologist Data in Germany.
Pharmacoepidemiology and drug safety. 2016;25(Suppl 3):652


Collings S, Johnson M, Kloss S, Ridha E, Evans D, Maguire A, et al., editors.
Early treatment persistence of oral anticoagulants in patients with non-valvular atrial fibrillation in the real-world setting: Findings from a German study using primary care data.
ESC; 2016


Collings S, Johnson M, Kloss S, Evans D, Maguire A, Lefèvre C.
Differences in Recording of Characteristics Among Patients Prescribed Oral Anticoagulants Using Primary Care and Cardiologist Data in Germany.
Pharmacoepidemiology and drug safety. 2016;25(S3):S1122
ICPE2016.


Collings S, Johnson M, Kloss S, Evans D, Maguire A, Lefèvre C.
How Complete Are Primary Care and Cardiologist Data in Germany for Research of Oral Anticoagulants in Non-Valvular Atrial Fibrillation?
Pharmacoepidemiology and drug safety. 2016;25(Suppl 3):200
ICPE2016.


Arriegas M, Rubino A.
Additional Risk Minimisation Measures Targeting Patients in the PRAC Era: A Qualitative Review of the European Public Assessment Report Database.
Pharmacoepidemiology and drug safety. 2016;25(Suppl 3):288.


Artime E, Qizilbash N, Rubino A.
Additional risk minimisation measures to prevent medication errors in the EU.
Pharmacoepidemiology and drug safety. 2016;25(Suppl):291.


Alfaro-Oliver N, Qizilbash N, Rubino A.
Quantitative and qualitative methods to support therapeutic risk minimization efforts.
Pharmacoepidemiology and drug safety. 2016;25(Suppl 3):290.


ISPE 2016
Servitja S, Zamora P, Santaballa A, GarcĂ­a J, de Paz L, Plata Y, et al.
Abstract P5-08-43: CASCADE study: Longer overall survival in the novo versus recidivant patients with locally advanced/metastatic breast cancer.
Cancer Res 2016;76:P5-08-43-P5-08-43.


Zamora P, Servitja S, Santaballa A, GarcĂ­a J, de Paz L, Plata Y, et al.
Abstract P3-07-39: CASCADE study: Treatment and clinical outcomes of metastatic breast cancer by tumor immunophenotypes.
Cancer Res 2016;76:P3-07-39-P3-07-39.
https://cancerres.aacrjournals.org/content/76/4_Supplement/P3-07-39


Alcázar B, de Lucas P, Soriano JB, Fernandez-Nistal A, Fuster A, González-Moro JM, et al.
The evaluation of a remote support program on quality of life and evolution of disease in COPD patients with frequent exacerbations.
BMC Pulm Med. 2016;16(1):140.


Requena G, De Abajo F, Huerta C, Evans SJ, Douglas I.
Does the Length of the “Pre-Exposure” Window Affect the Relative Risk Estimate? A Self-Controlled Case Series Study.
Pharmacoepidemiology and drug safety. 2015:580.


Qizilbash N, Gregson J, Johnson M, Pearce N, Douglas I, Wing K, et al.
Body mass index and risk of dementia in a cohort study of two million people in UK primary care database.
Pharmacoepidemiology and drug safety. 2015;24:371.0.1002/pds.3838


Lefevre C, Johnson M, Maguire A, Collings S, Kloss S, Evans D, editors.
Novel Oral Anticoagulant Treatment Persistence Among Patients With Non-valvular Atrial Fibrillation In The UK.
AHA; 2015


Lefevre C, Johnson M, Maguire A, Collings S, Kloss S, Evans D.
Patient Profile of New Users of Novel Oral Anticoagulants in non-Valvular Atrial Fibrillation (Nvaf): Real-World Evidence from Primary Care Data in Germany.
Value Health. 2015;18(7):A375.10.1016/j.jval.2015.09.776


Feudjo-Tepie M, Priedane E, Gonzalez del Castillo A, Maguire A.
Systematic literature review on the Epidemiology of male osteoporosis in Europe
Osteoporosis International. 2015;26(Suppl 1):S173


Benhaddi H, Johnson M, Maguire A, Collings S, Evans D, Budd D.
Patient profile of oral anticoagulation (OAC) use in people with non-valvular atrial fibrillation (NVAF): Findings from REACT-AF 2 study in UK primary care data.
European Heart Journal. 2015;24((S1)):659


Artime E, Rubino A, Qizilbash N.
A qualitative and quantitative review of additional risk minimisation measures for EU centrally Authorised products, 2006-2014.
Drug Safety. 2015;38(10):

­
Martínez Dueñas E, Zamora P, Servitja S, Santaballa A, García Mata J, De Paz L, et al.
1882 CASCADE study: Epidemiological analysis of current natural history and treatment patterns of metastatic breast cancer in Spain.
Eur J Cancer 2015;51:S293–4.


Romero Acebal M, Sánchez Ortiz C, Villalobos Chávez F, Rubio Esteban G, Redondo Verge L, Romero Godoy J, et al.
Efecto de lacosamida en control de la epilepsia y trastornos neuropsicolĂłgicos de ansiedad y depresiĂłn.
Sociedad Espanola de NeurologĂ­a; Valencia, Spain2014.


Toussi M, Lis Y, Qizilbash N, Blake KV, Ehrenstein V, Kurz X, et al.
Encepp-HTA Working Group Survey on Capacity To Conduct Research in Support Of Health Technology Assessment. vol. 17. 2014.


Romero Acebal M, Sánchez Ortiz C, Villalobos Chávez F, Rubio Esteban G, Redondo Verge L, Romero Godoy J, et al.
Effect Of Lacosamide On Seizure control And Neuropsychological Performance: Anxiety, Depression and Quality Of Life.
American Epilepsy Society2014.


Mendoza A, Santoyo F, Agulló A, Fenández-Cañamaque JL, Vivó C.
Manejo del dolor asociado a las curas en pacientes con quemaduras graves (P056).
SED; Toledo, Spain2014.


Cebolla J, De La Morena G, Garcia­Pavia P, Ripoll T, Rilo I, J.R. Gimeno­Blanes JR, et al.
Dried blood spot screening of Fabry Disease among patients with left ventricular hypertrophy of unknown cause.
European Society of Cardiology Congress2014.


Bedenbaugh AV, Qizilbash N, Dunkel J, SanJose B, Mendez I.
Real-World Utilization of Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in the United Kingdom.
ISPOR2014.


García-Sicilia López, Giménez Sánchez F, Lambermont C, Marcelon L, Qizilbash N, Weber F.
Observational post-authorisation safety study to describe the safety profile of the diphteria, tetanus and acellular pertussis vaccine (Triaxis®) as a 5th dose in 4-6 year old Spanish Children.
7th Vaccine ISV Annual Global Congress 2013.

PĂ©rez LĂłpez J, Giraldo P, Nunez R, Fernandez de la Puebla R, Luno E, S S-G, et al.
Epidemiological assessment of Spanish patients with type 1 Gaucher disease using the therapeutic goals MAP Tool®.
Molecular Genetics and Metabolism. 2011;114(2):S92-S3.10.1016/j.ymgme. 2014.12.206
ENCePP SIG on Measuring the Impact of Pharmacovigilance Activities
Contribution to Annex 2. Guidance on methods for pharmacovigilance impact research


Qizilbash N, Mendez I, Badiola C.
Letter to the Editor.
J Med Econ 2013;16:41–41.


Qizilbash N, Mendez I, Sanchez-de la Rosa R.
Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Clin Ther 2012;34:159–176.e5.


Qizilbash N, Mendez I.
Trends in utilization and off-label use of polyethylene glycol 4000 laxatives and the prevalence of constipation in children in France.
Clin Exp Gastroenterol 2011;4:181–8.


Blak BT, Wilson K, Metcalfe M, Maguire A, Hards M.
Evaluation of varenicline as an aid to smoking cessation in UK general practice - a THIN database study.
Curr Med Res Opin. 2010;26(4):861-70.


Lefevre C, Johnson M, Benhaddi H, Maguire A, Collings S, Evans D, et al.
Persistence to vitamin-K antagonists (VKA) and novel oral anticoagulants (NOAC) in patients with non-valvular atrial fibrillation (NVAF): Findings from REACT-AF 2 Study in UK primary care data.
PLoS One. 2017 Oct 10;12(10):e0185642. doi: 10.1371/journal.pone.0185642. eCollection 2017.

· Manuscripts
Artime A, Shui I, Mendez, Tcherny-Lessenot S, D'Arbigny P, Alfaro N, Qizilbash N.
Pre/Post Effectiveness Evaluation of Updated Additional Risk Minimisation Measures for an Orphan Disease: Myozyme (alglucosidase alfa)
Safety Information Packet. Pharmacoepidemiol Drug Saf. Accepted: Pending publication.

Artime E, Qizilbash N, Garrido-Estepa M, Vora P, Soriano-Gabarro M, Asiimwe A, et al.
Are risk minimization measures for approved drugs in Europe effective? A systematic review.
Expert Opin Drug Saf. 2019;18(5):443-54.


Vora P, Artime E, Soriano-Gabarro M, Qizilbash N, Singh V, Asiimwe A.
A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
Pharmacoepidemiology and drug safety. 2018;27(7):695-706.


Collings SL, Vannier-Moreau V, Johnson ME, Stynes G, Lefevre C, Maguire A, et al.
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
Archives of Cardiovascular Diseases 2018;111(5):370-9


Brieger D*, Pocock SJ, Blankenberg S, Chen J-Y, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D, Yasuda S, Gregson J, Rennie KL, Hedman K, Andersson-Sundell K, for the TIGRIS Study Investigators.
Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries.
Submitted to European Heart Journal in August 2018


Stuart J. Pocock, PhD; David Brieger, MD, PhD; John Gregson, PhD; Ji Yan Chen, MD; Mauricio G. Cohen, MD; Shaun G. Goodman, MD, MSc; Christopher B. Granger, MD; Richard Grieve PhD, Jose C. Nicolau, MD, PhD; Tabassome Simon, MD, PhD; Dirk Westermann MD; Satoshi Yasuda, MD, PhD, Katarina Hedman, PhD; Kirsten Rennie, PhD; Karolina Andersson-Sundell; for the TIGRIS Study Investigators.
A Novel Approach to Quantifying Risk of Major Cardiovascular Events in Patients 1–3 Years Post Myocardial Infarction: Insights from a Global Prospective Registry
Submitted to JAMA August 2018


Artime E, Qizilbash N, Rubino A.
Additional Risk Minimisation Measures to Prevent Medication Errors in the EU.
ISPE2018.


Artime E, Shui I, Tcherny-Lessenot S, D’Arbigny P, Mendez I, Qizilbash N.
Pre/Post Effectiveness Evaluation of the Myozyme (alglucosidase alfa) Safety Information Packet.
ISPE2018.


Haro JM, Altamura C, Corral R, Elkis H, Evans J, Krebs MO, et al.
Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study.
Psychiatry Res 2018;267:56–62.


Gisbert J., GomollĂłn F., MĂ©ndez I.
Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain.
Gastroenterol Hepatol 2018;41.


Westermann D, Goodman SG, Nicolau JC, Requena G, Maguire A, Chen JY, et al.
Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study.
Clinical cardiology. 2017;40(12):1197-204.


Rubino A, Artime E.
A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.
Expert Opin Drug Saf. 2017;16(8):877-84.


Maguire A, Johnson ME, Denning DW, Ferreira GLC, Cassidy A.
Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis.
Pharmacoepidemiology and drug safety. 2017;26(7):785-91.


Lamy FX, Saragoussi D, Johnson ME, Guiraud-Diawara A, Jorgensen KT, Loze JY, et al.
The use of adjunctive antipsychotics to treat depression in UK primary care.
Current medical research and opinion. 2017;33(5):891-8.


Goodman SG, Nicolau JC, Requena G, Maguire A, Blankenberg S, Chen JY, et al.
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
International journal of cardiology. 2017;236:54-60.


Collings S, Lefèvre C, Johnson M, Evans D, Hack G, Stynes G, et al.
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
PLoS One. 2017;12(10):e0185642.


Austin G. Stack BTB, Michelle E. Johnson, Victoria L. Parsons, Lewis Carpenter, Andrew Maguire, Alyssa B. Klein, Robert Morlock.
Association of gout control with reduced incidence of kidney failure in the UK health system.
EDTA2017.


Mendoza A, Santoyo FL, Agulló A, Fenández-Cañamaque JL, Vivó C.
The management of pain associated with wound care in severe burn patients in Spain.
Int J Burn Trauma. 2016;6(1):1-10


Johnson M, Lefèvre C, Collings S, Evans D, Kloss S, Ridha E, et al.
Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care.
BMJ Open. 2016;6(9) e011471.


Alcazar B, de Lucas P, Soriano JB, Fernandez-Nistal A, Fuster A, Gonzalez-Moro JM, et al.
The evaluation of a remote support program on quality of life and evolution of disease in COPD patients with frequent exacerbations.
BMC Pulm Med. 2016;16(1):140.


ArĂ­stegui J, Ferrer J, Salamanca I, Garrote E, Partidas A, San-Martin M, et al.
Multicenter prospective study on the burden of rotavirus gastroenteritis in children less than 3 years of age in Spain.
BMC Infect Dis 2016;16:1–12.


Giraldo P, Pérez-López J, Núñez R, de la Puebla RF, Luño E, Saura-Grau S, et al.
Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.
Blood Cells Mol Dis 2016;56:23–30.


Sanchez F G, GarcĂ­a-Sicilia J, Lambermont G, Bruyere I, Qizilbash N, Marcelon L.
Safety Profile of the Tetanus-Diphtheria-Acellular Pertussis Combination Vaccine as a Single Booster (5th dose) among Spanish Children Aged 4-6 years Old with Different Vaccination Schedules.
Journal of Vaccines & Vaccination. 2015;06(03).


Qizilbash N, Gregson J, Johnson M, Pearce N, Douglas I, Wing K, et al.
BMI and risk of dementia in two million people over two decades: a retrospective cohort study.
The Lancet Diabetes and Endocrinology 3. 2015;3(6):431-6.


Miravitlles M, Garcia-Sidro P, Fernandez-Nistal A, Buendia MJ, Espinosa de Los Monteros MJ, Esquinas C, et al.
The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD.
Int J Chron Obstruct Pulmon Dis. 2015;10:2571-9.


Maguire A, Mitchell BD, Ruzafa JC.
Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study.
BMC Endocr Disord. 2014;14:73.


Zamorano J, Serra V, Perez de Isla L, Feltes G, Calli A, Barbado FJ, et al.
Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Eur J Echocardiogr. 2011;12(9):671-7.
· The Lancet

N Qizilbash, J Gregson, ME Johnson, N Pearce, I Douglas, K Wing, SJW Evans, SJ Pocock. 2015. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. The Lancet Diabetes and Endocrinology, 3(6): 431 – 436.

G Whitlock, S Lewington, P Sherliker, R Clarke, J Emberson, J Halsey, N Qizilbash, R Collins, and R Peto. 2009. “Body-Mass Index and Cause-Specific Mortality in 900 000 Adults: Collaborative Analyses of 57 Prospective Studies.” The Lancet 373(9669): 1083–96.

S Lewington, G Whitlock, R Clarke, P Sherliker, J Emberson, J Halsey, N Qizilbash, R Peto, and R Collins. 2007. “Blood Cholesterol and Vascular Mortality by Age, Sex, and Blood Pressure: A Meta-Analysis of Individual Data from 61 Prospective Studies with 55,000 Vascular Deaths.” The Lancet 370(9602): 1829–39.

S Lewington, R Clarke, N Qizilbash, R Peto, and R Collins. 2002. “Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies.” The Lancet 360(9349): 1903–13.

Prospective Studies Collaboration. 1995. “Cholesterol, Diastolic Blood Pressure, and Stroke: 13 000 Strokes in 450 000 People in 45 Prospective Cohorts.” The Lancet 346(8991-8992): 1647–53.

JM Giné, A Maguire, and O Ramis-Juan. 1991. “Fatal Road Accidents in Catalonia.” The Lancet 338: 122–23.

R Collins, R Peto, S MacMahon, P Hebert, NH Fiebach, KA Eberlein, J Godwin, N Qizilbash, JO Taylor, and CH Hennekens. 1990. “Blood Pressure, Stroke, and Coronary Heart Disease. Part 2, Short-Term Reductions in Blood Pressure: Overview of Randomised Drug Trials in Their Epidemiological Context.” The Lancet 335(8693): 827–38.

· BMJ

N Qizilbash, L Jones, C Warlow, and J Mann. 1991.  'Fibrinogen and Lipid Concentrations as Risk Factors for Transient Ischaemic Attacks and Minor Ischaemic Strokes.' BMJ 303(6803): 605'9.

Antiplatelet Trialists' Collaboration. 1994. 'Collaborative Overview of Randomised Trials of Antiplatelet Therapy--I: Prevention of Death, Myocardial Infarction, and Stroke by Prolonged Antiplatelet Therapy in Various Categories of Patients.'BMJ'308(6921): 81'106.

Antiplatelet Trialists' Collaboration. 1988. 'Secondary Prevention of Vascular Disease by Prolonged Antiplatelet Treatment. Antiplatelet Trialists' Collaboration.'BMJ'296(6618): 320'31.

< 12 >
Copyright © 2013 Oxon All Rights Reserved - Late phase CRO